Loading clinical trials...

COMPLETEDPHASE1

Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers

Phase1a, Randomized Placebo-controlled, Single and Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNI-362 in Healthy Aged Volunteers 50 to 72 Years of Age

NCT04074837•Neuronascent, Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to examine the safety, tolerability and pharmacokinetics of single and multiple doses of NNI-362 in healthy aged population.

Detailed Description

The early clinical development strategy consists of the initial evaluation of safety and tolerability of NNI-362. This FIH Phase I includes single and multiple ascending dose studies in healthy aged volunteers. Assessment of suicidal ideation/behavior will be performed at baseline and at all study visits and on days of inpatient confinement in conformance with FDA recommendations.

Eligibility

Age

50 - 72 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy aged volunteers of either sex between the ages of 50 and 72 inclusive at time of screening.
•* Subjects must be in reasonably good health as determined by investigator based on medical history, vital signs measurements, physical examination, screening laboratory results and ECG.
•* Normal age-related findings as well as well-controlled, chronic and stable medical conditions (e.g., hypertension, osteoarthritis, non-insulin dependent diabetes mellitus, osteoporosis, gout, Paget's disease, hypothyroidism) will not be exclusionary if they are not expected to compromise subject safety, study conduct, or study objectives.
•* Non-interacting medications for stable allowable medical conditions will be allowed following review and approval by the medical monitor.
•* An adequate understanding of the requirements of the study, provision of written informed consent, and agreement to abide by the study restrictions.
•* Negative urine screen for drugs of abuse within 24 h before the administration of the first dose of study drug and in the multiple dose study upon readmission to the clinical unit from outpatient status.
•* Body Mass Index (BMI) of between 18 and 30 kg/m2 inclusive, and a total body weight greater than 48kg at screening.

Exclusion Criteria

•• Women of child-bearing potential, defined as premenopausal (unless the potential research subject has previously undergone hysterectomy and/or bilateral salpingo-oophorectomy)
•* Pregnant or breastfeeding
•* Any clinically significant hematology, chemistry, coagulation, or urinalysis value at screening and day -1 Abnormal liver enzymes (ALT and/or AST \>1.5X ULN) at screening and day -1
•* Serum creatinine \> ULN at screening and day -1
•* Hemoglobin \<13 g/dL for males or \<11.5 g/dL for females, leukocytes \<3.0 X 103/uL, absolute neutrophil count \<1000/uL, or platelets \<150 X 103/uL at screening and day -1
•* Any significant medical illness that could compromise the interpretability of study data or affect subject safety including, but not necessarily limited to:
•* Chronic pulmonary disease or sleep apnea
•* Clinically significant cardiac arrhythmia (either at screening or based on history)
•* Congestive heart failure, valvular heart disease or ischemic heart disease
•* Pulmonary hypertension
+11 more criteria

Locations (1)

Parexel, International

Glendale, California, United States

Key Dates

Start Date

August 1, 2019

Primary Completion Date

July 31, 2021

Completion Date

August 15, 2021

Last Updated

February 17, 2023

Enrollment

ACTUAL participants

Conditions

Alzheimer Disease

Interventions

NNI-362

DRUG

Placebo

DRUG

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive SymptomsDepression+2 more

View study

RECRUITINGNA

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

NCT07178210

Alzheimer DiseaseLymphatic Obstruction

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 17, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers

Inclusion Criteria

Exclusion Criteria

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Longitudinal Early-onset Alzheimer's Disease Study Protocol

A Study of AMDX-2011P in Participants With Alzheimer's Disease